Baxter Announces Acquisition of PerClot Polysaccharide Hemostatic System to Expand Advanced Surgery Portfolio
PerClot launches Baxter into the attractive hemostatic powder segment, while expanding our surgical offerings and complementing our recent acquisition of Seprafilm Adhesion Barrier.
- PerClot launches Baxter into the attractive hemostatic powder segment, while expanding our surgical offerings and complementing our recent acquisition of Seprafilm Adhesion Barrier.
- The trial evaluated the safety and efficacy of PerClot in achieving intraoperative hemostasis compared to the control (a similar marketed hemostatic powder).
- Combined use of PerClot PHS with other topical hemostatic agents has not been studied in controlled clinical trials.
- This release includes forward-looking statements concerning a definitive agreement entered into by Baxter to acquire PerClot Polysaccharide Hemostatic System from CryoLife, including expectations regarding the financial impact and other benefits of such acquisition for Baxter.